Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
PHILADELPHIA, Feb. 15, 2017 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Wednesday, Feb. 22, 2017, at 8:30 a.m. EST to discuss corporate and financial results for the year that ended Dec. 31, 2016.
The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 69899623. To access a live audio webcast, please visit the “Investors” section at www.sparktx.com.
A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 69899623, or by visiting the “Investors” section at www.sparktx.com.
About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, voretigene neparvovec, in development for the treatment of biallelic RPE65-mediated IRD, has received orphan designations in the U.S. and European Union, and breakthrough therapy designation in the U.S. The pipeline also includes SPK-7001 in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001 (which also has received both breakthrough therapy and orphan product designations) in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer, and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more about us and our growing pipeline, visit www.sparktx.com.
Investor Contact: Ryan Asay [email protected] (215) 239-6424 Media Contact: Monique da Silva [email protected] 215-282-7470
